Who
Lesley Ann Calhoun
Director
Company insider
Files Form 4 as: Director, Tango Therapeutics; Officer and Other, Aligos Therapeutics; Officer, Global Blood Therapeutics.
In numbers
- Trades disclosed
- 101
- Buys
- 0
- Sells
- 17
- Bought
- $0
- Sold
- $2.7M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 1 Mar 2017
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,485 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,485 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,185 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,250 at $0.00 | filing |
| 28 Feb 2025filed 4 Mar 2025 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,271 at $0.00 | filing |
| 4 Sep 2024filed 6 Sep 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,880 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,250 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $36K5,000 at $7.21 | filing |
| 1 Mar 2024filed 4 Mar 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —308,940 at $0.00 | filing |
| 28 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,833 at $0.00 | filing |
| 28 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,998 at $0.00 | filing |
| 28 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,750 at $0.00 | filing |
| 27 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —176,237 at $0.00 | filing |
| 27 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —105,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.